WASHINGTON, June 24, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2024 on Tuesday, July 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The... Read more
Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics WASHINGTON, June 19, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher” or the “Company”), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr.... Read more
Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer Move reflects increasing investment in AI as driving force for innovation and productivity. Company will host Innovation Summit in December focused on AI in R&D. WASHINGTON, June 5, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR), a global science and technology innovator,... Read more
Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research The Thermo Scientific™ Stellar™ mass spectrometer combines speed and sensitivity to advance precision medicine ANAHEIM, Calif.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Stellar™ mass spectrometer (MS), a new solution that combines fast... Read more
Bruker Applied Mass Spectrometry Division Showcases High-Performance Solutions for Research and Analysis in Applied Laboratories ANAHEIM, Calif.–(BUSINESS WIRE)– The Bruker Applied Mass Spectrometry Division is showcasing some of its latest innovations at ASMS 2024: EVOQ® DART-TQ⁺ mass spectrometer: A high-speed, chromatography-free solution for applied markets (Photo: Business Wire) New EVOQ® DART-TQ+ system for chromatography-free triple-quadrupole... Read more
timsTOF Ultra 2 enables significant further improvements in deep, high-fidelity 4D-Proteomics™ of mammalian cells, cancer cell lines, or tissue biopsies With sensitivity to measure >1000 proteins on just 25 pg, the timsTOF Ultra 2 opens new cell and disease biology research windows into PBMCs, small immune cells, bacterial cells, or subcellular organelle proteomics timsTOF Ultra... Read more
neofleX is a versatile, high-performance, and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers neofleX Imaging Profiler MALDI-TOF/TOF with proprietary smartbeam 3D laser neofleX and MALDI HiPLEX-IHC technology enable protein tissue imaging Multiomics MSI correlation of targeted proteins with glycans, metabolites, lipids, endogenous peptides, and now also mid-plex mRNA/DNA-ISH More insights per pixel... Read more
BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) announced today it will present at the following conferences: 2024 Jefferies Global Healthcare Conference, New York, NY Thursday, June 6, 2024, at 7:30 a.m. Eastern Time Frank Laukien, Chairman, President and Chief Executive Officer Juergen Srega, President, Bruker CALID Group 45th Annual Goldman Sachs Global Healthcare Conference, Miami,... Read more
BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (“Bruker” or the “Company”) (Nasdaq: BRKR) today announced the pricing of its previously announced underwritten registered public offering of 6,000,000 shares of its common stock. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock. The offering is... Read more
BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (“Bruker” or the “Company”) (Nasdaq: BRKR) today announced the launch of an underwritten registered public offering of 6,000,000 shares of its common stock. In addition, Bruker expects to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock. The offering is subject... Read more